研究者業績

桑原 聡

クワバラ サトシ  (Satoshi Kuwabara)

基本情報

所属
千葉大学 大学院医学研究院脳神経内科学 教授 (教授)
学位
医学博士(1993年3月 千葉大学)

J-GLOBAL ID
200901033727459280
researchmap会員ID
1000200574

論文

 964
  • Hiroki Masuda, Masahiro Mori, Akiyuki Uzawa, Tomohiko Uchida, Ryohei Ohtani, Shigeo Kobayashi, Satoshi Kuwabara
    Journal of the Neurological Sciences 385 64-68 2018年2月15日  査読有り
    Fatigue and pain are disabling symptoms in patients with neuromyelitis optica spectrum disorder (NMOSD). The Modified Fatigue Impact Scale (MFIS) has not yet been validated in patients with NMOSD, and anti-interleukin-6 (IL-6) receptor antibody was reported to decrease pain and fatigue in patients with NMOSD. The aim of this study was to validate MFIS and to investigate the relationships among fatigue, pain and serum IL-6 levels in patients with NMOSD. MFIS and the Multidimensional Fatigue Inventory (MFI), an established scale for fatigue, were administered to patients with NMOSD and age- and sex-matched healthy controls (HCs). The Pain Effects Scale score and serum IL-6 levels were also measured in patients with NMOSD. Correlations among clinical characteristics, laboratory data and each score were investigated. To validate MFIS in patients with NMOSD, MFIS was administered twice within 4 days from the first administration. Fifty-one patients answered the first MFIS, and 26 patients answered the second MFIS. There was no difference between the first and second MFIS scores. Patients with NMOSD had higher MFIS and MFI scores than HCs. No correlations were observed between serum IL-6 levels and either score. MFIS was validated in patients with NMOSD. Serum IL-6 levels may not be involved in the pathogenesis of fatigue and pain in patients with NMOSD.
  • Atsuhiko Sugiyama, Noriko Sato, Yasuhiro Nakata, Yukio Kimura, Mikako Enokizono, Tomoko Maekawa, Madoka Kondo, Yuji Takahashi, Satoshi Kuwabara, Hiroshi Matsuda
    Journal of neurology 265(2) 322-329 2018年2月  査読有り
    Dentatorubral-pallidoluysian atrophy (DRPLA) is an autosomal dominant spinocerebellar ataxia caused by CAG triplet expansion in atrophin 1 and is frequently associated with cerebral white matter lesions. To elucidate the clinical features of elderly onset DRPLA and the key radiological findings for differentiating DRPLA from physiological white matter lesions in healthy elderly subjects, we reviewed the clinical and magnetic resonance imaging (MRI) features of ten patients with elderly onset genetically confirmed DRPLA (> 60 years) and compared their MRI findings with those of age- and sex-matched ten healthy subjects with asymptomatic cerebral white matter lesions. The initial symptom was cerebellar ataxia in all DRPLA patients, and five of them did not have any symptoms other than ataxia at the time of MRI examination. Atrophy of the brainstem, superior cerebellar peduncle, and cerebellum was detected in all DRPLA patients and none of the healthy subjects. Abnormal signals in the brainstem (inferior olive, pons, and midbrain), thalamus, and cerebellar white matter were frequently observed in elderly onset DRPLA patients but not in healthy subjects. In conclusion, elderly onset DRPLA presents as cerebellar ataxia alone in the early stage of disease. Atrophy of the brainstem, superior cerebellar peduncle, and cerebellum and abnormal signals in the brainstem, cerebellum, and thalamus are key findings for differentiating elderly onset DRPLA from asymptomatic cerebral white matter lesions in healthy subjects.
  • Satoshi Kuwabara, Sonoko Misawa, Masahiro Mori
    Clinical and Experimental Neuroimmunology 9(1) 47-53 2018年2月1日  
    Chronic inflammatory demyelinating polyneuropathy (CIDP) is a heterogeneous disorder having a wide range of clinical phenotypes, and is currently classified into “typical CIDP” and variants, such as multifocal acquired demyelinating sensory and motor neuropathy. Typical CIDP is clinically characterized by symmetric polyneuropathy involving proximal as well as distal muscle weakness, whereas electrophysiology shows evidence of demyelination predominant in the distal nerve terminals, and magnetic resonance neurography frequently shows prominent hypertrophy of the nerve roots. The pattern of demyelination distribution strongly suggests primary involvement of the nerve terminals and roots, where the blood–nerve barrier is anatomically deficient, and the importance of an antibody-mediated mechanism. In contrast, multifocal acquired demyelinating sensory and motor neuropathy is multiple mononeuropathy or asymmetric polyneuropathy with multifocal conduction blocks and focal nerve enlargement in the intermediate nerve trunks at the site of conduction block such distribution of lesions is reasonably explained by breakdown of the blood–nerve barrier by activated lymphocytes, suggesting a multiple sclerosis-like cellular mechanism. Clinical features are likely to be determined by the immunopathogenesis, and therefore different immunological treatment would be required for each CIDP subtype. The present review focuses on current concepts of the disease spectrum of “CIDP syndrome” deciphered by electrophysiology and neuroimaging.
  • Kunihiro Yoshida, Satoshi Kuwabara, Katsuya Nakamura, Ryuta Abe, Akira Matsushima, Minako Beppu, Yoshitaka Yamanaka, Yuji Takahashi, Hidenao Sasaki, Hidehiro Mizusawa
    Journal of the neurological sciences 384 30-35 2018年1月15日  査読有り
    Cortical cerebellar atrophy (CCA) and multiple system atrophy with predominant cerebellar ataxia (MSA-C) are the two major forms of adult-onset sporadic ataxia. Contrary to MSA-C, there are neither diagnostic criteria nor neuroimaging features pathognomonic for CCA. Therefore, it is assumed that the category of CCA in the Japanese national registry include heterogeneous cerebellar ataxic disorders. To refine this category in more detail, we here used a clinical-based term, "idiopathic cerebellar ataxia (IDCA)", and proposed its diagnostic criteria. We collected 346 consecutive patients with the core features of the criteria (sporadic, insidious-onset and slowly progressive cerebellar ataxia in adults, and cerebellar atrophy on brain imaging). Of these, 212 (61.3%) were diagnosed with probable or possible MSA, and 30, who did not meet the diagnostic criteria for MSA at examination, were also excluded because of MRI findings suggestive of MSA. Twenty two were proven to have hereditary spinocerebellar ataxias by genetic testing, and 19 had secondary ataxias. Finally, the remaining 63 (18.2%) were diagnosed with IDCA. The mean (standard deviation) age at onset was 57.2 (10.8) years. Of these, 25 (39.7%) showed pure cerebellar ataxia, and the remaining 38 (60.3%) had some of extracerebellar features including abnormal tendon reflexes (46.0%), positive Babinski sign (9.5%), sensory disturbance (12.7%), cognitive impairment (9.5%), and involuntary movements (7.9%). Our results show that IDCA refined by the diagnostic criteria still includes clinically and genetically heterogeneous ataxic disorders. More extensive genetic analyses will be of significance for further clarification of this group.
  • Takehito Iwase, Hirotaka Yokouchi, Sonoko Misawa, Toshiyuki Oshitari, Takayuki Baba, Satoshi Kuwabara, Shuichi Yamamoto
    Neuro-Ophthalmology 42(1) 25-30 2018年1月2日  査読有り
    © 2017 Taylor & Francis. The authors present findings in a 39-year-old man with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome with bilateral optic disc oedema. He was successfully treated with bortezomib and dexamethasone followed by autologous peripheral blood stem cell transplantation. The peripapillary retinal thickness was reduced in the optical coherence tomographic (OCT) images along with a decrease of the serum vascular endothelial growth factor (VEGF) levels. The authors recommend OCT to monitor the changes in the signs of POEMS syndrome after treatments.
  • Ai Ishikawa, Masaki Tokunaga, Jun Maeda, Takeharu Minamihisamatsu, Masafumi Shimojo, Hiroyuki Takuwa, Maiko Ono, Ruiqing Ni, Shigeki Hirano, Satoshi Kuwabara, Bin Ji, Ming-Rong Zhang, Ichio Aoki, Tetsuya Suhara, Makoto Higuchi, Naruhiko Sahara
    Journal of Alzheimer's disease : JAD 61(3) 1037-1052 2018年  査読有り
    BACKGROUND: Tau imaging using PET is a promising tool for the diagnosis and evaluation of tau-related neurodegenerative disorders, but the relationship among PET-detectable tau, neuroinflammation, and neurodegeneration is not yet fully understood. OBJECTIVE: We aimed to elucidate sequential changes in tau accumulation, neuroinflammation, and brain atrophy by PET and MRI in a tauopathy mouse model. METHODS: rTg4510 transgenic (tg) mice expressing P301L mutated tau and non-tg mice were examined with brain MRI and PET imaging (analyzed numbers: tg = 17, non-tg = 13; age 2.5∼14 months). As PET probes, [11C]PBB3 (Pyridinyl-Butadienyl-Benzothiazole 3) and [11C]AC-5216 were used to visualize tau pathology and 18-kDa translocator protein (TSPO) neuroinflammation. Tau pathology and microglia activation were subsequently analyzed by histochemistry. RESULTS: PET studies revealed age-dependent increases in [11C]PBB3 and [11C]AC-5216 signals, which were correlated with age-dependent volume reduction in the forebrain on MRI. However, the increase in [11C]PBB3 signals reached a plateau at age 7 months, and therefore its significant correlation with [11C]AC-5216 disappeared after age 7 months. In contrast, [11C]AC-5216 showed a strong correlation with both age and volume reduction until age 14 months. Histochemical analyses confirmed the relevance of pathological tau accumulation and elevated TSPO immunoreactivity in putative microglia. CONCLUSION: Our results showed that tau accumulation is associated with neuroinflammation and brain atrophy in a tauopathy mouse model. The time-course of the [11C]PBB3- and TSPO-PET finding suggests that tau deposition triggers progressive neuroinflammation, and the sequential changes can be evaluated in vivo in mouse brains.
  • Hao Wang, Xiao-Meng Zhang, Go Tomiyoshi, Rika Nakamura, Natsuko Shinmen, Hideyuki Kuroda, Risa Kimura, Seiichiro Mine, Ikuo Kamitsukasa, Takeshi Wada, Akiyo Aotsuka, Yoichi Yoshida, Eiichi Kobayashi, Tomoo Matsutani, Yasuo Iwadate, Kazuo Sugimoto, Masahiro Mori, Akiyuki Uzawa, Mayumi Muto, Satoshi Kuwabara, Minoru Takemoto, Kazuki Kobayashi, Harukiyo Kawamura, Ryoichi Ishibashi, Koutaro Yokote, Mikiko Ohno, Po-Min Chen, Eiichiro Nishi, Koh Ono, Takeshi Kimura, Toshio Machida, Hirotaka Takizawa, Koichi Kashiwado, Hideaki Shimada, Masaaki Ito, Ken-Ichiro Goto, Katsuro Iwase, Hiromi Ashino, Akiko Taira, Emiko Arita, Masaki Takiguchi, Takaki Hiwasa
    Oncotarget 9(5) 5600-5613 2018年  査読有り
    Transient ischemic attack (TIA) is a predictor for cerebral infarction (CI), and early diagnosis of TIA is extremely important for the prevention of CI. We set out to identify novel antibody biomarkers for TIA and CI, and detected matrix metalloproteinase 1 (MMP1), chromobox homolog 1 (CBX1), and chromobox homolog 5 (CBX5) as candidate antigens using serological identification of antigens by recombinant cDNA expression cloning (SEREX) and Western blotting to confirm the presence of serum antibodies against the antigens. Amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA) revealed that serum antibody levels were significantly higher in patients with TIA or acute-phase CI (aCI) compared with healthy donors (P &lt 0.01). Spearman's correlation analysis and multivariate logistic regression analysis demonstrated that levels of anti-MMP1, anti-CBX1, and anti-CBX5 antibodies were associated with age, cigarette-smoking habits, and blood pressure. Thus, serum levels of antibodies against MMP1, CBX1, and CBX5 could potentially serve as useful tools for diagnosing TIA and predicting the onset of aCI.
  • Ohtani R, Mori M, Uchida T, Uzawa A, Masuda H, Liu J, Kuwabara S
    Multiple sclerosis journal - experimental, translational and clinical 4(1) 2055217318759692 2018年1月  査読有り
  • Shigeki Hirano, Hitoshi Shinotoh, Hitoshi Shimada, Tsuneyoshi Ota, Koichi Sato, Noriko Tanaka, Ming-Rong Zhang, Makoto Higuchi, Kiyoshi Fukushi, Toshiaki Irie, Satoshi Kuwabara, Tetsuya Suhara
    Journal of Alzheimer's Disease 62(4) 1539-1548 2018年  査読有り
    Background: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by chronic progressive cognitive decline and displays underlying brain cholinergic dysfunction, providing a rationale for treatment with cholinomimetic medication. The clinical presentations and courses of AD patients may differ by age of onset. Objective: The objective of the present study was to illustrate the regional differences of brain acetylcholinesterase (AChE) activity as quantified by N-[11C]methylpiperidinyl-4-acetate ([11C]MP4A) and PET using parametric whole brain analysis and clarify those differences as a function of age. Methods: 22 early onset AD (EOAD) with age at onset under 65, the remaining 26 as late onset AD (LOAD), and 16 healthy controls (HC) were enrolled. Voxel-based AChE activity estimation of [11C]MP4A PET images was conducted by arterial input and unconstrained nonlinear least-squares method with subsequent parametrical analyses. Statistical threshold was set as Family Wise Error corrected, p-value &lt 0.05 on cluster-level and cluster extent over 30 voxels. Results: Voxel-based group comparison showed that, compared to HC, both EOAD and LOAD showed cortical AChE decrement in parietal, temporal, and occipital cortices, with wider and stringent cortical involvement in the EOAD group, most prominently demonstrated in the temporal region. There was no significant correlation between age and regional cerebral AChE activity except for a small left superior temporal region in the AD group (Brodmann's area 22, Zmax = 5.13, 396 voxels), whereas no significant cluster was found in the HC counterpart. Conclusion: Difference in cortical cholinergic dysfunction between EOAD and LOAD may shed some light on the cholinomimetic drug efficacy in AD.
  • Borisow N, Mori M, Kuwabara S, Scheel M, Paul F
    Frontiers in neurology 9 888 2018年  査読有り
  • Ivo N van Schaik, on behalf of the, Vera Bril, Nan van Geloven, Hans-Peter Hartung, Richard A Lewis, Gen Sobue, John-Philip Lawo, Michaela Praus, Orell Mielke, Billie L Durn, David R Cornblath, Ingemar S J Merkies, A. Sabet, K. George, L. Roberts, R. Carne, S. Blum, R. Henderson, P. Van Damme, J. Demeestere, S. Larue, C. D'Amour, V. Bril, A. Breiner, P. Kunc, M. Valis, J. Sussova, T. Kalous, R. Talab, M. Bednar, T. Toomsoo, I. Rubanovits, K. Gross-Paju, U. Sorro, M. Saarela, M. Auranen, J. Pouget, S. Attarian, G. Le Masson, A. Wielanek-Bachelet, C. Desnuelle, E. Delmont, P. Clavelou, D. Aufauvre, J. Schmidt, J. Zschuentssch, C. Sommer, D. Kramer, O. Hoffmann, C. Goerlitz, J. Haas, M. Chatzopoulos, R. Yoon, R. Gold, P. Berlit, A. Jaspert-Grehl, D. Liebetanz, A. Kutschenko, M. Stangel, C. Trebst, P. Baum, F. Bergh, J. Klehmet, A. Meisel, F. Klostermann, J. Oechtering, H. Lehmann, M. Schroeter, T. Hagenacker, D. Mueller, A. Sperfeld, F. Bethke, V. Drory, A. Algom, D. Yarnitsky, B. Murinson, A. Di Muzio, F. Ciccocioppo, S. Sorbi, S. Mata, A. Schenone, M. Grandis, G. Lauria, D. Cazzato, G. Antonini, S. Morino, D. Cocito, M. Zibetti, T. Yokota, T. Ohkubo, T. Kanda, M. Kawai, K. Kaida, H. Onoue, S. Kuwabara, M. Mori, M. Iijima, K. Ohyama, M. Baba, M. Tomiyama, K. Nishiyama, T. Akutsu, K. Yokoyama, K. Kanai, I. N. van Schaik, F. Eftimov, N. C. Notermans, N. Visser, C. Faber, J. Hoeijmakers, K. Rejdak, U. Chyrchel-Paszkiewicz, C. Casanovas Pons, M. Alberti Aguiló, J. Gamez, M. Figueras, C. Marquez Infante, S. Benitez Rivero, M. Lunn, J. Morrow, D. Gosal, T. Lavin, I. Melamed, A. Testori, S. Ajroud-Driss, D. Menichella, E. Simpson, E. Chi-Ho Lai, M. Dimachkie, R. J. Barohn, S. Beydoun, H. Johl, D. Lange, A. Shtilbans, S. Muley, S. Ladha, M. Freimer, J. Kissel, N. Latov, R. Chin, E. Ubogu, S. Mumfrey, T. Rao, P. MacDonald, K. Sharma, G. Gonzalez, J. Allen, D. Walk, L. Hobson-Webb, K. Gable
    The Lancet Neurology 17(1) 35-46 2018年1月1日  査読有り
    Background Approximately two-thirds of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) need long-term intravenous immunoglobulin. Subcutaneous immunoglobulin (SCIg) is an alternative option for immunoglobulin delivery, but has not previously been investigated in a large trial of CIDP. The PATH study compared relapse rates in patients given SCIg versus placebo. Methods Between March 12, 2012, and Sept 20, 2016, we studied patients from 69 neuromuscular centres in North America, Europe, Israel, Australia, and Japan. Adults with definite or probable CIDP who responded to intravenous immunoglobulin treatment were eligible. We randomly allocated participants to 0·2 g/kg or 0·4 g/kg of a 20% SCIg solution (IgPro20) weekly versus placebo (2% human albumin solution) for maintenance treatment for 24 weeks. We did randomisation in a 1:1:1 ratio with an interactive voice and web response system with a block size of six, stratified by region (Japan or non-Japan). The primary outcome was the proportion of patients with a CIDP relapse or who were withdrawn for any other reason during 24 weeks of treatment. Patients, caregivers, and study personnel, including those assessing outcomes, were masked to treatment assignment. Analyses were done in the intention-to-treat and per-protocol sets. This trial is registered with ClinicalTrials.gov, number NCT01545076. Findings In this randomised, double-blind, placebo-controlled trial, we randomly allocated 172 patients: 57 (33%) to the placebo group, 57 (33%) to the low-dose group, and 58 (34%) to the high-dose group. In the intention-to-treat set, 36 (63% [95% CI 50–74]) patients on placebo, 22 (39% [27–52]) on low-dose SCIg, and 19 (33% [22–46]) on high-dose SCIg had a relapse or were withdrawn from the study for other reasons (p=0·0007). Absolute risk reductions were 25% (95% CI 6–41) for low-dose versus placebo (p=0·007), 30% (12–46) for high-dose versus placebo (p=0·001), and 6% (−11 to 23) for high-dose versus low-dose (p=0·32). Causally related adverse events occurred in 47 (27%) patients (ten [18%] in the placebo group, 17 [30%] in the low-dose group, and 20 [34%] in the high-dose group). Six (3%) patients had 11 serious adverse events: one (2%) patient in the placebo group, three (5%) in the low-dose group, and two (3%) in the high-dose group only one (an acute allergic skin reaction in the low-dose group) was assessed to be causally related. Interpretation This study, which is to our knowledge, the largest trial of CIDP to date and the first to study two administrations of immunoglobulins and two doses, showed that both doses of SCIg IgPro20 were efficacious and well tolerated, suggesting that SCIg can be used as a maintenance treatment for CIDP. Funding CSL Behring.
  • Yamagishi Y, Suzuki H, Sonoo M, Kuwabara S, Yokota T, Nomura K, Chiba A, Kaji R, Kanda T, Kaida K, Ikeda SI, Mutoh T, Yamasaki R, Takashima H, Matsui M, Nishiyama K, Sobue G, Kusunoki S
    Journal of the peripheral nervous system : JPNS 22(4) 433-439 2017年12月  査読有り
  • Akiyuki Hiraga, Satoshi Kuwabara
    CEPHALALGIA 37(13) 1310-1310 2017年11月  査読有り
  • Shingo Suzuki, Sonoko Misawa, Takahiro Ota, Yu Li, Satoshi Kuwabara, Masatomi Ikusaka
    AMERICAN JOURNAL OF MEDICINE 130(11) E491-E492 2017年11月  査読有り
  • Keisuke Suzuki, Yasuyuki Okuma, Tomoyuki Uchiyama, Masayuki Miyamoto, Ryuji Sakakibara, Yasushi Shimo, Nobutaka Hattori, Satoshi Kuwabara, Toshimasa Yamamoto, Yoshiaki Kaji, Shigeki Hirano, Ayaka Numao, Koichi Hirata
    PARKINSONISM & RELATED DISORDERS 44 18-22 2017年11月  査読有り
    Background: We investigated the prevalence and impact of restless legs syndrome (RLS) and leg motor restlessness (LMR) in patients with Parkinson's disease (PD) in a multicenter study.Methods: A total of 436 PD patients and 401 age- and sex-matched controls were included in this study. RLS was diagnosed based on four essential features. LMR was diagnosed when a participant exhibited the urge to move his or her legs but did not meet the four essential features of RLS.Results: The RLS prevalence did not differ between PD patients and controls (3.4% vs. 2.7%), while LMR prevalence was significantly higher in PD patients than in controls (12.8% vs. 4.5%). PD patients with RLS or LMR had a higher prevalence of excessive daytime sleepiness (EDS) (50.7%, vs. 6.9%), probable REM sleep behavior disorder (38.0% vs. 3.4%) and PD-related sleep problems (49.3% vs. 20.7%) than controls with RLS or LMR. RLS/LMR preceding PD onset was related to an older age of PD onset.Conclusion: Our study revealed an increased prevalence of LMR but not RLS in PD patients. LMR could be an early manifestation of PD; however, whether LMR is within the range of RLS or whether LMR and RLS constitute different entities in PD requires further studies. (C) 2017 Elsevier Ltd. All rights reserved.
  • Keisuke Suzuki, Yasuyuki Okuma, Tomoyuki Uchiyama, Masayuki Miyamoto, Ryuji Sakakibara, Yasushi Shimo, Nobutaka Hattori, Satoshi Kuwabara, Toshimasa Yamamoto, Yoshiaki Kaji, Shigeki Hirano, Taro Kadowaki, Koichi Hirata
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 88(11) 953-959 2017年11月  査読有り
    Objectives To investigate the impact of sleep disturbances on Parkinson's disease (PD) clinical motor subtypes and disease-related disability in a multicentre setting.Methods We report a cross-sectional relationship between sleep-related symptoms and clinical motor subtypes (tremor dominant (TD); intermediate; postural instability and gait disturbances (PIGDs)) identified in a multicentre study, including 436 patients with PD and 401 age-matched controls. PD-related sleep problems (PD-SP), excessive daytime sleepiness (EDS) and probable REM sleep behaviour disorder (pRBD) were evaluated using the PD sleep scale (PDSS)-2, Epworth Sleepiness Scale (ESS) and RBD screening questionnaire-Japanese version (RBDSQ-J), respectively.Results PD-SP (PDSS-2 >= 18; 35.1% vs 7.0%), EDS (ESS >= 10; 37.8% vs 15.5%) and pRBD (RBDSQ-J >= 5; 35.1% vs 7.7%) were more common in patients with PD than in controls. The prevalence of restless legs syndrome did not differ between patients with PD and controls (3.4% vs 2.7%). After adjusting for age, sex, disease duration and Movement Disorder Society-Unified PD Rating Scale (MDS-UPDRS) part III score, the PIGD group had higher PDSS-2 and ESS scores than the TD group. The RBDSQ-J scores did not differ among the TD, intermediate and PIGD groups. A stepwise regression model predicting the MDS-UPDRS part II score identified the Hoehn and Yahr stage, followed by the number of sleep-related symptoms (PD-SP, EDS and pRBD), disease duration, MDS-UPDRS part III score, PIGD subtype, depression and MDS-UPDRS part IV score as significant predictors.Conclusion Our study found a significant relationship between sleep disturbances and clinical motor subtypes. An increased number of sleep-related symptoms had an impact on disease-related disability.
  • Tetsuya Kanai, Akiyuki Uzawa, Yasunori Sato, Shigeaki Suzuki, Naoki Kawaguchi, Keiichi Himuro, Fumiko Oda, Yukiko Ozawa, Jin Nakahara, Norihiro Suzuki, Yuko K. Takahashi, Satoru Ishibashi, Takanori Yokota, Takashi Ogawa, Kazumasa Yokoyama, Nobutaka Hattori, Shoko Izaki, Satoru Oji, Kyoichi Nomura, Juntaro Kaneko, Kazutoshi Nishiyama, Ichiro Yoshino, Satoshi Kuwabara
    ANNALS OF NEUROLOGY 82(5) 841-849 2017年11月  査読有り
    ObjectiveMyasthenia gravis (MG) is an autoimmune disease mostly caused by autoantibodies against acetylcholine receptor associated with thymus abnormalities. Thymectomy has been proven to be an efficacious treatment for patients with MG, but postoperative myasthenic crisis often occurs and is a major complication. We aimed to develop and validate a simple scoring system based on clinical characteristics in the preoperative status to predict the risk of postoperative myasthenic crisis. MethodsWe studied 393 patients with MG who underwent thymectomy at 6 tertiary centers in Japan (275 patients for derivation and 118 for validation). Clinical characteristics, such as gender, age at onset and operation, body mass index, disease duration, MG subtype, severity, symptoms, preoperative therapy, operative data, and laboratory data, were reviewed retrospectively. A multivariate logistic regression with LASSO penalties was used to determine the factors associated with postoperative myasthenic crisis, and a score was assigned. Finally, the predictive score was evaluated using bootstrapping technique in the derivation and validation groups. ResultsMultivariate logistic regression identified 3 clinical factors for predicting postoperative myasthenic crisis risk: (1) vital capacity<80%, (2) disease duration<3 months, and (3) bulbar symptoms immediately before thymectomy. The postoperative myasthenic crisis predictive score, ranging from 0 to 6 points, had areas under the curve of 0.84 (0.66-0.96) in the derivation group and 0.80 (0.62-0.95) in the validation group. InterpretationA simple scoring system based on 3 preoperative clinical characteristics can predict the possibility of postoperative myasthenic crisis. Ann Neurol 2017;82:841-849
  • Atsuhiko Sugiyama, Daichi Sone, Noriko Sato, Yukio Kimura, Miho Ota, Norihide Maikusa, Tomoko Maekawa, Mikako Enokizono, Madoka Mori-Yoshimura, Yasushi Ohya, Satoshi Kuwabara, Hiroshi Matsuda
    PLOS ONE 12(11) e0187343 2017年11月  査読有り
    This study aimed to investigate abnormalities in structural covariance network constructed from gray matter volume in myotonic dystrophy type 1 (DM1) patients by using graph theoretical analysis for further clarification of the underlying mechanisms of central nervous system involvement. Twenty-eight DM1 patients (4 childhood onset, 10 juvenile onset, 14 adult onset), excluding three cases from 31 consecutive patients who underwent magnetic resonance imaging in a certain period, and 28 age-and sex-matched healthy control subjects were included in this study. The normalized gray matter images of both groups were subjected to voxel based morphometry (VBM) and Graph Analysis Toolbox for graph theoretical analysis. VBM revealed extensive gray matter atrophy in DM1 patients, including cortical and subcortical structures. On graph theoretical analysis, there were no significant differences between DM1 and control groups in terms of the global measures of connectivity. Betweenness centrality was increased in several regions including the left fusiform gyrus, whereas it was decreased in the right striatum. The absence of significant differences between the groups in global network measurements on graph theoretical analysis is consistent with the fact that the general cognitive function is preserved in DM1 patients. In DM1 patients, increased connectivity in the left fusiform gyrus and decreased connectivity in the right striatum might be associated with impairment in face perception and theory of mind, and schizotypal-paranoid personality traits, respectively.
  • A. Sugiyama, N. Sato, Y. Kimura, T. Maekawa, M. Enokizono, Y. Saito, Y. Takahashi, H. Matsuda, S. Kuwabara
    AMERICAN JOURNAL OF NEURORADIOLOGY 38(11) 2100-2104 2017年11月  査読有り
    Neuronal intranuclear inclusion disease is a neurodegenerative disorder pathologically characterized by eosinophilic hyaline intranuclear inclusions. A high-intensity signal along the corticomedullary junction on DWI has been described as a specific MR imaging finding of the cerebrum in neuronal intranuclear inclusion disease. However, MR imaging findings of the cerebellum in neuronal intranuclear inclusion disease have not been fully evaluated. Here, we review MR imaging findings of the cerebellum in a series of 8 patients with pathologically confirmed neuronal intranuclear inclusion disease. The MR imaging results showed cerebellar atrophy (8/8 patients) and high-intensity signal on FLAIR images in the medial part of the cerebellar hemisphere right beside the vermis (the "paravermal area") (6/8) and in the middle cerebellar peduncle (4/8). The paravermal abnormal signals had a characteristic distribution, and they could be an indicator of the diagnosis of neuronal intranuclear inclusion disease even when using the results of past MR imaging examinations in which DWI findings were not examined.
  • Nobusada Funabashi, Sonoko Misawa, Hiroyuki Takaoka, Koya Ozawa, Satoshi Kuwabara, Yoshio Kobayashi
    CIRCULATION 136 2017年11月  
    0
  • Atsuta N, Yokoi D, Nakamura R, Watanabe H, Hayashi N, Ito M, Watanabe H, Katsuno M, Izumi Y, Morita M, Taniguchi A, Oda M, Abe K, Mizoguchi K, Kano O, Kuwabara S, Aoki M, Hattori N, Kaji R, Sobue G
    JOURNAL OF THE NEUROLOGICAL SCIENCES 381 103-103 2017年10月15日  
  • Yokoi D, Atsuta N, Hirakawa A, Nakamura R, Watanabe H, Hayashi N, Ito M, Watanabe H, Katsuno M, Izumi Y, Morita M, Taniguchi A, Oda M, Abe K, Mizoguchi K, Kano O, Kuwabara S, Kaji R, Sobue G
    JOURNAL OF THE NEUROLOGICAL SCIENCES 381 720-721 2017年10月15日  
  • Akiyuki Hiraga, Yuya Aotsuka, Kyosuke Koide, Satoshi Kuwabara
    CEPHALALGIA 37(11) 1102-1105 2017年10月  査読有り
    Background Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by segmental vasospasm. Vasoactive agents and childbirth have been reported as precipitating factors for RCVS; however, RCVS induced by altitude change or air travel has rarely been reported. Case We present a case of a 74-year-old woman who presented with thunderclap headache during airplane descent. Magnetic resonance angiography demonstrated segmental vasoconstriction that improved 9 days after onset. Conclusion These findings indicate that airplane descent may be a trigger of RCVS. The time course of headache in the present case was similar to that of prolonged headache attributed to airplane travel, indicating that RCVS during air travel may have previously been overlooked and that some headache attributed to airplane travel cases may represent a milder form of RCVS.
  • Tatsuya Yamamoto, Masato Asahina, Yoshitaka Yamanaka, Tomoyuki Uchiyama, Shigeki Hirano, Miki Fuse, Yasuko Koga, Ryuji Sakakibara, Satoshi Kuwabara
    JOURNAL OF THE NEUROLOGICAL SCIENCES 381 230-234 2017年10月  査読有り
    Objective: It is difficult to differentiate multiple system atrophy (MSA) from Parkinson's disease (PD) at least in the early stage. Urodynamic study (UDS) is useful in differentiating MSA from PD. We aimed to clarify which UDS parameter was useful in differentiating MSA from PD.Methods: We retrospectively reviewed 273 cases and performed UDS and external anal sphincter electromyography (EAS-EMG) in patients with MSA (n = 182) and PD (n = 91). We analyzed the utility of UDS parameters, including postvoid residuals (PVR), detrusor overactivity (DO), degree of bladder contraction, and mean duration of motor unit potentials (MUPs) in EAS-EMG, for differentiating MSA from PD.Results: PVR > 150 ml during free-flow study strongly indicated MSA rather than PD (OR 8.723, 95% CI 2.612-29.130, p < 0.001). 'Weak detrusor' also suggested MSA, but it was not a statistically significant indicator (OR 10.598, 95% CI 0.359-312.473, p = 0.172). DO and neurogenic changes in EAS-EMG (mean duration of MUPs > 10 ms). did not significantly contribute to the differentiation of MSA from PD.Conclusions: PVR > 150 ml during free-flow study might be more useful than other UDS parameters in clinically differentiating MSA from PD.
  • Satoshi Kuwabara, Masahiro Mori, Sonoko Misawa, Miki Suzuki, Kazutoshi Nishiyama, Tatsuro Mutoh, Shizuki Doi, Norito Kokubun, Mikiko Kamijo, Hiroo Yoshikawa, Koji Abe, Yoshihiko Nishida, Kazumasa Okada, Kenji Sekiguchi, Ko Sakamoto, Susumu Kusunoki, Gen Sobue, Ryuji Kaji
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 88(10) 832-838 2017年10月  査読有り
    Objective Short-term efficacy of induction therapy with intravenous immunoglobulin (Ig) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) is well established. However, data of previous studies on maintenance therapy were limited up to 24-week treatment period. We aimed to investigate the efficacy and safety of longer-term intravenous Ig therapy for 52 weeks. Methods This study was an open-label phase 3 clinical trial conducted in 49 Japanese tertiary centres. 49 patients with CIDP who fulfilled diagnostic criteria were included. After an induction intravenous Ig therapy (0.4 g/kg/day for five consecutive days), maintenance dose intravenous Ig (1.0g/kg) was given every 3 weeks for up to 52 weeks. The primary outcome measures were the responder rate at week 28 and relapse rate at week 52. The response and relapse were defined with the adjusted Inflammatory Neuropathy Cause and Treatment scale. Results At week 28, the responder rate was 77.6% (38/49 patients; 95% CI 63% to 88%), and the 38 responders continued the maintenance therapy. At week 52, 4 of the 38 (10.5%) had a relapse (95% CI 3% to 25%). During 52 weeks, 34 (69.4%) of the 49 enrolled patients had a maintained improvement. Adverse events were reported in 94% of the patients; two patients (66-year-old and 76-year-old men with hypertension or diabetes) developed cerebral infarction (lacunar infarct with good recovery), and the other adverse effects were mild and resolved by the end of the study period. Conclusions Maintenance treatment with 1.0 g/kg intravenous Ig every 3 weeks is an efficacious therapy for patients with CIDP, and approximately 70% of them had a sustained remission for 52 weeks. Thrombotic complications should be carefully monitored, particularly in elderly patients with vascular risk factors.
  • Ryuji Sakakibara, Fuyuki Tateno, Masahiko Kishi, Yohei Tsuyusaki, Yosuke Aiba, Hitoshi Terada, Tsutomu Inaoka, Setsu Sawai, Satoshi Kuwabara, Fumio Nomura
    JOURNAL OF MOVEMENT DISORDERS 10(3) 116-122 2017年9月  査読有り
    Objective Diagnosis of sporadic cerebellar ataxia is a challenge for neurologists. A wide range of potential causes exist, including chronic alcohol use, multiple system atrophy of cerebellar type (MSA-C), and sporadic late cortical cerebellar atrophy. Recently, an autosomal-dominant spinocerebellar ataxia (SCA) mutation was identified in a cohort of patients with non-MSA-C sporadic cerebellar ataxia. The aim of this study is to genetically screen genes involved in SCA in a Japanese single-hospital cohort.Methods Over an 8-year period, 140 patients with cerebellar ataxia were observed. There were 109 patients with sporadic cerebellar ataxia (no family history for at least four generations, 73 patients with MSA-C, and 36 patients with non-MSA-C sporadic cerebellar ataxia) and 31 patients with familial cerebellar ataxia. We performed gene analysis comprising SCA1, 2, 3, 6, 7, 8, 12, 17, 31, and dentatorubro-pallidoluysian atrophy (DRPLA) in 28 of 31 non-MSA-C sporadic patients who requested the test. Familial patients served as a control.Results Gene abnormalities were found in 57% of non-MSA-C sporadic cerebellar ataxia cases. Among patients with sporadic cerebellar ataxia, abnormalities in SCA6 were the most common (36%), followed by abnormalities in SCA1 (7.1%), SCA2 (3.6%), SCA3 (3.6%), SCA8 (3.6%), and DRPLA (3.6%). In contrast, gene abnormalities were found in 75% of familial cerebellar ataxia cases, with abnormalities in SCA6 being the most common (29%). For sporadic versus familial cases for those with SCA6 abnormalities, the age of onset was older (69 years vs. 59 years, respectively), and CAG repeat length was shorter (23 vs. 25, respectively) in the former than in the latter (not statistically significant).Conclusion Autosomal-dominant mutations in SCA genes, particularly in SCA6, are not rare in sporadic cerebellar ataxia. The reason for the frequency of mutations in SCA6 remains unclear; however, the reason may reflect a higher age at onset and variable penetrance of SCA6 mutations.
  • S. Isose, K. Watanabe, S. Omori, Y. Sekiguchi, M. Beppu, K. Shibuya, H. Amino, T. Suichi, S. Misawa, S. Kuwabara
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM 22(3) 305-305 2017年9月  
  • Y. Yamagishi, H. Suzuki, Masahiro Sonoo, Satoshi Kuwabara, Takanori Yokota, Kyoichi Nomura, Atsuro Chiba, Ryuji Kaji, Takashi Kanda, Kenichi Kaida, Shuichi Ikeda, Tatsuro Mutoh, Junichi Kira, Hiroshi Takashima, Makoto Matsui, Gen Sobue, Kazutoshi Nishiyama, S. Kusunoki
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM 22(3) 412-412 2017年9月  
  • T. Suichi, S. Misawa, Y. Sato, M. Beppu, Y. Sekiguchi, K. Shibuya, K. Watanabe, H. Amino, S. Kuwabara
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM 22(3) 390-390 2017年9月  
  • Keisuke Suzuki, Yasuyuki Okuma, Tomoyuki Uchiyama, Masayuki Miyamoto, Ryuji Sakakibara, Yasushi Shimo, Nobutaka Hattori, Satoshi Kuwabara, Toshimasa Yamamoto, Koichi Hirata
    CEPHALALGIA 37 228-229 2017年9月  
  • S. Kuwabara, S. Misawa, Y. Sekiguchi, Susumu Kusunoki
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM 22(3) 323-323 2017年9月  
  • S. Misawa, Y. Sato, K. Katayama, Y. Sekiguchi, H. Amino, T. Suichi, S. Kuwabara
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM 22(3) 342-342 2017年9月  
  • H. Amino, S. Misawa, Y. Sekiguchi, K. Shibuya, K. Watanabe, T. Suichi, S. Kuwabara
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM 22(3) 235-235 2017年9月  
  • Omori S, Isose S, Misawa S, Watanabe K, Sekiguchi Y, Shibuya K, Beppu M, Amino H, Kuwabara S
    Neuroscience research 121 43-48 2017年8月  査読有り
  • Masahiro Mori, Akiyuki Uzawa, Satoshi Kuwabara
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 88(8) 620-620 2017年8月  
  • Tatsuya Yamamoto, Tomoyuki Uchiyama, Yoshinori Higuchi, Masato Asahina, Shigeki Hirano, Yoshitaka Yamanaka, Liu Weibing, Satoshi Kuwabara
    JOURNAL OF THE NEUROLOGICAL SCIENCES 379 18-21 2017年8月  査読有り
    Introduction: We aimed to examine temporal changes in health-related quality of life (HRQOL) and its relationship with motor and cognitive functions in patients with Parkinson's disease (PD) after subthalamic nucleus deep brain stimulation (STN-DBS). Methods: In total, 31 patients with PD were enrolled in this study (mean age: 66.7 +/- 0.9 years; mean disease duration: 11.6 +/- 3.7 years). Participants completed the Unified Parkinson's Disease Rating Scale and the Parkinson's Disease Questionnaire-39. Cognitive function was assessed using the Mini Mental State Examination, the Frontal Assessment Battery, and the Montreal Cognitive Assessment. Postoperative evaluation was performed at three months, one year, three years, and five years after surgery; temporal changes in the correlation between HRQOL and motor and cognitive functions were evaluated at all follow-up periods. Results: All patients completed postoperative clinical evaluations after three months, after one year. Of the 31 participants, twelve completed postoperative clinical evaluations after three years and seven after five years. Motor functions showed significant improvement over the five-year follow-up period. The mobility subdomain of the HRQOL worsened whereas the total score did not change significantly over years. Cognitive functions were not significantly impaired during follow-up periods. HRQOL was basically not significantly correlated with motor and cognitive functions during the follow-up period. Conclusions: The mobility subdomain of the HRQOL worsened after surgery, and the improvement in motor functions was basically not correlated with HRQOL after STN-DBS in patients with PD. Cognitive functions were not significantly impaired during follow-up periods. (C) 2017 Published by Elsevier B.V.
  • Hiroki Masuda, Shigeki Hirano, Nobuyoshi Takahashi, Etsuko Hatsugano, Akiyuki Uzawa, Tomohiko Uchida, Ryohei Ohtani, Satoshi Kuwabara, Masahiro Mori
    PLOS ONE 12(8) e0184012 2017年8月  査読有り
    Objective Brain regions responsible for cognitive dysfunction in MS and neuromyelitis optica spectrum disorder (NMOSD) are not known. Our aim of this study was to investigate whether cognitive function and brain volume differed between MS and NMOSD in Japanese patients. Methods Brain MRI and neuropsychological tests including the Wechsler Adult Intelligence Scale-III (WAIS-III), Wechsler Memory Scale-Revised (WMS-R), Trail Making Test (TMT) and Clinical Assessment for Attention (CAT) were performed. Parametric grey matter (GM) and white matter (WM) volumes determined from lesion-filled T1-weighted images using wholebrain voxel-based morphometry (VBM) were compared by two-tailed t test. Results Twenty relapsing-remitting MS and sixteen NMOSD patients were included. MS patients were younger than NMOSD patients. Processing speed intelligence quotient (IQ), general memory, verbal memory and delayed recall were significantly worse in MS patients than in NMOSD patients. Furthermore, left superior temporal gyrus (STG) GM volume was smaller in MS patients than in NMOSD patients (P &lt; 0.05, family-wise error [FWE] corrected, Zmax = 4.97, 62 voxel). The left STG GM volume tended to be positively correlated with delayed recall in MS patients. Conclusions Despite being younger, MS patients demonstrated worse performance in certain cognitive variables than NMOSD patients, which might be associated with left STG GM volume loss.
  • Tomohiko Uchida, Masahiro Mori, Akiyuki Uzawa, Hiroki Masuda, Mayumi Muto, Ryohei Ohtani, Satoshi Kuwabara
    MULTIPLE SCLEROSIS JOURNAL 23(8) 1072-1084 2017年7月  査読有り
    Background: Inflammation in neuromyelitis optica (NMO) is triggered by a serum antibody against the aquaporin-4 (AQP4). This process requires antibody penetration of the blood-brain barrier (BBB), but the mechanisms for BBB disruption in NMO remain unknown. Objective: We examined whether changes in cerebrospinal fluid (CSF) and serum matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs), and cytokines are associated with BBB disruption in NMO. Methods: The concentrations 9 MMPs, 4 TIMPs, and 14 cytokines were measured by multiplex assay in CSF and serum samples from 29 NMO patients, 29 relapsing-remitting multiple sclerosis (MS) patients, and 27 patients with other neurological disorders. We also performed immunohistochemistry for MMP-2 and TIMP-1 expression in post-mortem brain tissues from NMO patients. Results: NMO patients exhibited significantly elevated MMP-2, TIMP-1, interleukin-6, and MMP-2/TIMP-2 ratio in CSF (but not sera) than the other groups. The CSF/serum albumin ratio, an index of BBB permeability, was most strongly correlated with CSF MMP-2 concentration, which in turn correlated with CSF interleukin-6 levels. Immunohistochemistry revealed MMP-2- and TIMP-1-positive cells surrounding vessels in NMO lesions. Conclusion: In NMO, increased CSF MMP-2, likely induced by interleukin-6 signaling, may disrupt the BBB and enable serum anti-AQP-4 antibodies migration into the central nervous system (CNS).
  • Uncini A, Ippoliti L, Shahrizaila N, Sekiguchi Y, Kuwabara S
    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 128(7) 1176-1183 2017年7月  査読有り
  • T. Yamamoto, M. Asahina, Y. Yamanaka, T. Uchiyama, S. Hirano, M. Fuse, Y. Koga, R. Sakakibara, S. Kuwabara
    NEUROUROLOGY AND URODYNAMICS 36 S510-S512 2017年7月  
  • T. Uchiyama, T. Yamamoto, Y. Higuchi, K. Suzuki, T. Kadowaki, H. Fujita, Y. Watanabe, K. Kaga, T. Yamanishi, R. Sakakibara, K. Hirata, S. Kuwabara
    NEUROUROLOGY AND URODYNAMICS 36 S484-S484 2017年7月  
  • Hirotaka Yokouchi, Takayuki Baba, Sonoko Misawa, Masayasu Kitahashi, Toshiyuki Oshitari, Satoshi Kuwabara, Shuichi Yamamoto
    BRITISH JOURNAL OF OPHTHALMOLOGY 101(6) 786-790 2017年6月  査読有り
    Aims To determine the changes in the subfoveal choroidal thickness (CT), the foveal thickness (FT) and the serum level of vascular endothelial growth factor (VEGF) after thalidomide treatment in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes (POEMS) syndrome. Methods We studied 13 left eyes of 13 treatment-naive patients with POEMS syndrome. The subfoveal CT and FT were determined by enhanced depth imaging optical coherence tomography, and the serum level of VEGF was determined by ELISA at the baseline and at 6 months after thalidomide treatment. The correlations in the serum level of VEGF and the subfoveal CT or the FT at the baseline and at 6 months after treatment were determined. Results Together with the reduction in the serum level of VEGF, the subfoveal CT was also reduced significantly from 439.1 +/- 66.5 mm at the baseline to 307.2 +/- 75.4 mm at 6 months (p=0.001). The mean FT at the baseline was 236.4 +/- 30.7 mm which did not change significantly at 6 months at 228.1 +/- 33.1 mm (p&gt;0.05). The change in the subfoveal CT was significantly and linearly correlated with the change in the serum level of VEGF at 6 months after treatment (r=0.67, p=0.011). Conclusions The significant correlation between the CT and the serum level of VEGF may offer clues on the pathogenesis of ocular diseases of POEMS syndrome and on the role of serum VEGF on the choroid.
  • T. Yamamoto, M. Asahina, Y. Yamanaka, T. Uchiyama, S. Hirano, M. Fuse, Y. Koga, R. Sakakibara, S. Kuwabara
    MOVEMENT DISORDERS 32(1) e0169405 2017年6月  査読有り
  • Akiyuki Uzawa, Masahiro Mori, Hiroki Masuda, Ryohei Ohtani, Tomohiko Uchida, Setsu Sawai, Satoshi Kuwabara
    CLINICA CHIMICA ACTA 469 144-149 2017年6月  査読有り
    Background: Elevation of cerebrospinal fluid (CSF) interleukin (IL)-6 has been reported in various neurological disorders but has never been systematically analyzed. Our main objectives are to compare the CSF IL-6 levels among various neurological disorders and to evaluate the significance of CSF IL-6 measurements for the diagnosis of neuromyelitis optica (NMO). Methods: We retrospectively investigated the IL-6 levels of 572 consecutive CSF samples in patients with various neurological disorders. Additionally, the associations between clinical manifestations in NMO patients and CSF IL-6 levels were closely investigated. Results: Among the neurological disorders, patients with NMO had the highest CSF IL-6 level. Receiver operating characteristic analysis found the optimal cutoff CSF IL-6 value for diagnosing NMO as 7.8 pg/ml, and the sensitivity and specificity were 0.7317 and 0.7694, respectively. In NMO, CSF IL-6 levels were correlated with the length of the spinal cord lesion and anti-aquaporin-4 antibody-positivity and decreased after treatment. Conclusion: CSF IL-6 can be high in various inflammatory and non-inflammatory CNS disorders, but its upregulation appears to be the most remarkable in NMO. (C) 2017 Elsevier B.V. All rights reserved.
  • Satoshi Kuwabara, Sonoko Misawa, Masahiro Mori
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 88(6) 459-459 2017年6月  
  • Bart C. Jacobs, Bianca van den Berg, Christine Verboon, Govindsinh Chavada, David R. Cornblath, Kenneth C. Gorson, Thomas Harbo, Hans-Peter Hartung, Richard A. C. Hughes, Susumu Kusunoki, Pieter A. van Doorn, Hugh J. Willison, the IGOS Consortium, B. C. Jacobs, R. A.C. Hughes, D. R. Cornblath, K. C. Gorson, H. P. Hartung, S. Kusunoki, P. A. van Doorn, H. J. Willison, M. van Woerkom, B. van den Berg, C. Verboon, J. Roodbol, B. C. Jacobs, R. C. Reisin, S. W. Reddel, Z. Islam, B. Islam, Q. D. Mohammad, P. van den Bergh, T. E. Feasby, Y. Z. Wang, T. Harbo, Y. Péréon, H. P. Hartung, H. C. Lehmann, E. Dardiotis, E. Nobile-Orazio, S. Kusunoki, N. Shahrizaila, B. C. Jacobs, B. van den Berg, C. Verboon, K. Bateman, I. Illa, L. A. Querol, S. T. Hsieh, H. J. Willison, G. Chavada, A. Davidson, K. C. Gorson, J. M. Addington, S. Ajroud-Driss, H. Andersen, G. Antonini, S. Attarian, U. Badrising, F. A. Barroso, L. Benedetti, A. Beronio, M. Bianco, D. Binda, C. Briani, J. Bürmann, I. R. Bella, T. E. Bertorini, R. Bhavaraju-Sanka, T. H. Brannagan, M. Busby, S. Butterworth, M. Campagnolo, C. Casasnovas, G. Cavaletti, C. S. Chao, S. Chen, S. Chetty, K. G. Claeys, J. A. Cohen, M. E. Conti, J. S. Cosgrove, M. C. Dalakas, M. M. Dimachkie, U. Dillmann, C. Domínguez González, K. Doppler, C. Dornonville de la Cour, A. Echaniz-Laguna, F. Eftimov, C. G. Faber, R. Fazio, C. Fokke, T. Fujioka, E. A. Fulgenzi, G. Galassi, T. Garcia, M. Garnero, M. P.J. Garssen, C. J. Gijsbers, J. M. Gilchrist, H. J. Gilhuis, J. M. Goldstein, N. Goyal, V. Granit, A. Grapperon, G. Gutiérrez Gutiérrez, L. Gutmann, R. D.M. Hadden, J. V. Holbech, J. K.L. Holt, C. Homedes Pedret, M. Htut, K. Jellema, I. Jericó Pascual, K. Kaida, S. Karafiath, H. D. Katzberg, L. Kiers, B. C. Kieseier, K. Kimpinski, R. P. Kleyweg, N. Kokubun, N. A. Kolb, K. Kuitwaard, S. Kuwabara, J. Y. Kwan, S. S. Ladha, L. Landschoff Lassen, V. Lawson, D. Ledingham, L. Léon Cejas, C. A. Luciano, S. T. Lucy, M. P.T. Lunn, A. Magot, H. Manji, C. Marchesoni, G. A.M. Marfia, C. Márquez Infante, E. Martinez Hernandez, G. Mataluni, M. Mattiazi, C. J. McDermott, G. D. Meekins, J. Miller, M. S. Monges, M. C.J. Montero, G. Morís de la Tassa, C. Nascimbene, C. Neumann, R. J. Nowak, P. Orizaola Balaguer, M. Osei-Bonsu, E. B.L. Pan, J. Pardo Fernandez, M. Pasnoor, M. T. Pulley, Y. A. Rajabally, S. Rinaldi, C. Ritter, R. C. Roberts, I. Rojas-Marcos, S. A. Rudnicki, G. M. Sachs, J. P.A. Samijn, L. Santoro, D. S. Saperstein, A. Savransky, H. Schneider, A. Schenone, M. J. Sedano Tous, Y. Sekiguchi, K. A. Sheikh, N. J. Silvestri, S. H. Sindrup, C. L. Sommer, B. Stein, A. M. Stino, A. Spyropoulos, J. Srinivasan, H. Suzuki, S. W. Taylor, H. Tankisi, D. Tigner, P. T. Twydell, F. Valzania, P. van Damme, A. J. van der Kooi, G. W. van Dijk, T. van der Ree, R. van Koningsveld, J. D. Varrato, F. H. Vermeij, J. J.G.M. Verschuuren, L. H. Visser, M. V. Vytopil, W. Waheed, M. Wilken, C. Wilkerson, P. W. Wirtz, Y. Yamagishi, E. M. Yiu, L. Zhou, S. Zivkovic
    Journal of the Peripheral Nervous System 22(2) 68-76 2017年6月1日  査読有り
    Guillain-Barré syndrome (GBS) is an acute polyradiculoneuropathy with a highly variable clinical presentation, course, and outcome. The factors that determine the clinical variation of GBS are poorly understood which complicates the care and treatment of individual patients. The protocol of the ongoing International GBS Outcome Study (IGOS), a prospective, observational, multicenter cohort study that aims to identify the clinical and biological determinants and predictors of disease onset, subtype, course and outcome of GBS is presented here. Patients fulfilling the diagnostic criteria for GBS, regardless of age, disease severity, variant forms, or treatment, can participate if included within 2 weeks after onset of weakness. Information about demography, preceding infections, clinical features, diagnostic findings, treatment, course, and outcome is collected. In addition, cerebrospinal fluid and serial blood samples for serum and DNA is collected at standard time points. The original aim was to include at least 1,000 patients with a follow-up of 1–3 years. Data are collected via a web-based data entry system and stored anonymously. IGOS started in May 2012 and by January 2017 included more than 1,400 participants from 143 active centers in 19 countries across 5 continents. The IGOS data/biobank is available for research projects conducted by expertise groups focusing on specific topics including epidemiology, diagnostic criteria, clinimetrics, electrophysiology, antecedent events, antibodies, genetics, prognostic modeling, treatment effects, and long-term outcome of GBS. The IGOS will help to standardize the international collection of data and biosamples for future research of GBS.
  • T. Uchiyama, T. Yamamoto, K. Suzuki, T. Kadowaki, A. Numao, H. Fujita, Y. Watanabe, T. Matsubara, M. Miyamoto, K. Kaga, T. Yamanishi, R. Sakakibara, S. Kuwabara, K. Hirata
    MOVEMENT DISORDERS 32 2017年6月  
  • Hiroki Masuda, Masahiro Mori, Tomohiko Uchida, Akiyuki Uzawa, Ryohei Ohtani, Satoshi Kuwabara
    JOURNAL OF NEUROIMMUNOLOGY 305 102-107 2017年4月  査読有り
    Soluble CD40 ligand (sCD4OL) is reported to disrupt the blood-brain barrier (BBB). Cerebrospinal fluid (CSF) and serum sCD4OL levels were measured in 29 multiple sclerosis (MS), 29 neuromyelitis optica spectrum disorder (NMOSD), and 27 disease control (DC) patients. In MS, serum sCD4OL levels were higher than in DCs and positively correlated with the CSF/serum albumin ratio (Qalb). In NMOSD, CSF sCD4OL levels were significantly increased compared to DCs, and were correlated to Qalb, CSF cell counts, protein concentrations, and interleukin-6 levels. sCD4OL could be involved in BBB disruption in MS, whereas it may contribute to CNS inflammation in NMOSD. (C) 2017 Elsevier B.V. All rights reserved.
  • Mayumi Muto, Masahiro Mori, Jia Liu, Akiyuki Uzawa, Tomohiko Uchida, Hiroki Masuda, Ryohei Ohtani, Kazuo Sugimoto, Satoshi Kuwabara
    JOURNAL OF NEUROIMMUNOLOGY 305 131-134 2017年4月  査読有り
    Previously, we identified anti-Talin-1 antibodies in the serum of MS. In this case, we measured the serum soluble Talin-1 (sTalin-1) levels by enzyme-linked immunosorbent assay. The serum sTalin-1 levels were significantly higher in 40 patients with MS than in 43 normal controls and in the acute phase of disease than in the remission phase. Interestingly, serum sTalin-1 levels were associated with a sustained increase in disability after MS attack but not with serum anti-Talin-1 antibody levels. sTalin-1 may be a biomarker for the acute phase of MS and may be used for the short-term prognosis of MS. (C) 2017 Elsevier B.V. All rights reserved.
  • Satoshi Kuwabara, Akiyuki Uzawa, Masahiro Mori
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 88(4) 283-283 2017年4月  

MISC

 1029

書籍等出版物

 77

講演・口頭発表等

 84

担当経験のある科目(授業)

 3

共同研究・競争的資金等の研究課題

 64